Alnylam price target lowered to $176 from $184 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Alnylam to $176 from $184 and keeps an Equal Weight rating on the shares. Top-line data from the Phase 3 HELIOS-B study of Amvuttra in ATTR cardiomyopathy, or ATTR-CM, are expected in the first half of 2024, notes the firm, which estimates results could be provided in April. The firm sees potential for positive results, but does not have “high conviction” and sees a balanced risk/reward at current levels, adds the analyst, who sees 55% odds that the stock is likely up 30-50% on positive results and 45% odds that the stock is likely down 40% or more on negative ones.